17-Aug-2026
Stifel Nicolaus Sticks to Its Buy Rating for Lyell Immunopharma (LYEL)
TipRanks (Fri, 14-Aug 10:05 AM ET)
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Globe Newswire (Thu, 25-Jun 8:00 AM ET)
Globe Newswire (Fri, 12-Jun 12:45 PM ET)
Globe Newswire (Mon, 8-Jun 6:00 AM ET)
Globe Newswire (Thu, 4-Jun 4:05 PM ET)
Globe Newswire (Mon, 1-Jun 8:00 AM ET)
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Lyell Immunopharma trades on the NASDAQ stock market under the symbol LYEL.
As of August 17, 2026, LYEL stock price declined to $13.55 with 129,424 million shares trading.
LYEL has a beta of 2.48, meaning it tends to be more sensitive to market movements. LYEL has a correlation of 0.12 to the broad based SPY ETF.
LYEL has a market cap of $332.03 million. This is considered a Small Cap stock.
Last quarter Lyell Immunopharma reported $4,000 in Revenue and -$1.92 earnings per share. This fell short of revenue expectation by $-600 and exceeded earnings estimates by $.08.
In the last 3 years, LYEL traded as high as $65.11 and as low as $7.65.
The top ETF exchange traded funds that LYEL belongs to (by Net Assets): VTI, IWM, VXF, IWN, SCHA.
LYEL has outperformed the market in the last year with a price return of +25.9% while the SPY ETF gained +21.0%. However, in the short term, LYEL had mixed performance relative to the market. It has underperformed in the last 3 months, returning -28.8% vs +3.5% return in SPY. But in the last 2 weeks, LYEL shares have fared better than the market returning +4.7% compared to SPY +3.4%.
LYEL support price is $13.33 and resistance is $14.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LYEL shares will trade within this expected range on the day.